Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to $26.3 million.

  • Ani Pharmaceuticals' Net Income towards Common Stockholders rose 20692.25% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.0 million, marking a year-over-year increase of 54754.47%. This contributed to the annual value of -$20.1 million for FY2024, which is 21744.78% down from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Net Income towards Common Stockholders is $26.3 million, which was up 20692.25% from $8.1 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $26.3 million in Q3 2025 and a low of -$24.6 million during Q3 2024
  • Its 5-year average for Net Income towards Common Stockholders is -$2.4 million, with a median of -$2.7 million in 2024.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Net Income towards Common Stockholders tumbled by 2545185.19% in 2022, and later skyrocketed by 162323.33% in 2024.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Net Income towards Common Stockholders stood at -$24.3 million in 2021, then surged by 80.88% to -$4.6 million in 2022, then skyrocketed by 116.11% to $749000.0 in 2023, then crashed by 1526.17% to -$10.7 million in 2024, then soared by 345.96% to $26.3 million in 2025.
  • Its last three reported values are $26.3 million in Q3 2025, $8.1 million for Q2 2025, and $15.3 million during Q1 2025.